Episode Details

Lumos Diagnostics CEO Doug Ward joined Steve Darling from Proactive to discuss the company’s recent achievement of CLIA waiver status and the growing adoption of its FebriDx® rapid diagnostic test across the United States. Ward said FebriDx® is now being used at more than 100 healthcare locations across 18 states, including urgent care clinics, primary care practices, concierge medicine providers, and collegiate health centers. The rapid point-of-care test uses a simple fingerstick blood sample to help clinicians differentiate between bacterial infections and non-bacterial causes of illness, supporting faster treatment decisions and reducing unnecessary antibiotic prescriptions. The rollout follows the company’s receipt of CLIA waiver status, which significantly expands access to the test by allowing its use in a wider range of healthcare settings. As respiratory infections remain highly seasonal, Lumos is currently focused on onboarding new customers, integrating FebriDx® into clinical workflows, and preparing healthcare providers ahead of the upcoming respiratory season. Ward noted that establishing reimbursement pathways remains a key priority. The company reported that more than 90% of submitted reimbursement claims have been paid to date, with average payments exceeding the Medicare benchmark of US$41.38 per test. Lumos is using the traditionally slower spring and summer testing period to build market awareness, support pilot programs, expand customer adoption, and further demonstrate the clinical and economic value of FebriDx® in real-world healthcare environments. Management believes the growing adoption of FebriDx® highlights increasing demand for rapid, actionable diagnostic tools that can improve patient care, support antibiotic stewardship efforts, and enhance operational efficiency at the point of care. #proactiveinvestors #lumosdiagnosticsholdings #asx #ldx #otc #ldxhf #FebriDx #PointOfCare #HealthcareInnovation #Diagnostics #PointOfCareTesting #MedicalTechnology #AntibioticStewardship #Healthcare #RapidTesting #MedTech